ArticleApplied microbiology and biotechnology2026
Harnessing silica-coated silver nanoparticles for combating multidrug-resistant Pseudomonas aeruginosa.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) Pseudomonas aeruginosa poses a critical challenge in clinical settings because of its resistance to conventional antibiotics. This study investigated the antibacterial potential of silica-coated silver nanoparticles (SiO₂@AgNPs) against MDR P. aeruginosa and explored their synergistic interactions with selected antibiotics. A total of 450 pus samples were processed for bacterial isolation, and P. aeruginosa was identified using standard microbiological methods. MDR strains were confirmed using MIC-based VITEK antimicrobial susceptibility testing and RT-PCR for resistance genes. The antibacterial activity of the SiO₂@AgNPs was assessed using the microbroth dilution method. A checkerboard assay was conducted against MDR isolates to determine the synergy between SiO₂@AgNPs and ciprofloxacin, meropenem, and ceftazidime-avibactam. The synthesized nanoparticles were characterized using transmission electron microscopy (TEM), Fourier-transform infrared (FTIR) spectroscopy, and X-ray diffraction (XRD) analysis. Of the 450 pus samples, 100 P. aeruginosa isolates were identified, of which 13 were classified as MDR P. aeruginosa. SiO₂@AgNPs exhibited effective antibacterial activity, with an MIC of 500 µg/mL against MDR P. aeruginosa. Checkerboard assays demonstrated strong synergy with meropenem and ceftazidime-avibactam (FICI = 0.375) and partial synergy with ciprofloxacin (FICI = 0.625-1.0625). TEM revealed spherical particles with an average size of 10 nm, FTIR confirmed SiO₂ functional groups, and XRD revealed crystalline silver nanoparticles within an amorphous silica matrix. These findings indicate that SiO₂@AgNPs possess potent antibacterial activity against MDR P. aeruginosa and can enhance the efficacy of certain antibiotics, highlighting their potential in combination therapy against resistant strains. KEY POINTS: ● Silica-coated silver nanoparticles effectively inhibited MDR P. aeruginosa. ● SiO₂@AgNPs enhance the efficacy of meropenem and ceftazidime-avibactam. ● Nanoparticle-antibiotic combinations may offer new strategies for treating resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.